Ishita Drugs & Industries Ltd (ISHITADR) — shareholding pattern, promoter holding, financials and share price
About Ishita Drugs & Industries Ltd (ISHITADR)
Ishita Drugs & Industries Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ISHITADR and on the BSE under scrip code 524400. Its ISIN is INE806D01016.
Incorporated in 1992, Ishita Drugs & Industries Ltd is engaged in the manufacturing of various APIs and drug intermediates [1]
Ishita Drugs & Industries Limited specializes in manufacturing Active Pharma Ingredients, drug intermediates, fine chemicals, and excipients, with state-of-the-art production facilities.
The company boasts three key manufacturing facilities in Gujarat, dedicated to APIs, drug intermediates, and pharmaceutical formulations.
Listed peers in Pharmaceuticals: Venmax Drugs & Pharmaceuticals Ltd, Cian Healthcare Ltd, Centuple Global Ltd, Rekvina Labs Ltd, Mono Pharmacare Ltd, Desh Rakshak Aushdhalaya Ltd.
Valuation & Returns
10 Jul 2026At ₹73 a share on 10 Jul 2026, Ishita Drugs & Industries Ltd (ISHITADR) was valued at a price-to-earnings ratio of 27.99x against an industry P/E of 36.41x and a price-to-book of 2.02x on a book value of ₹36.08 per share as of Mar 2025. Solomo computes return on equity of 7.23% and return on capital employed of 7.76% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 27.99x
- Industry P/E
- 36.41x
- P/B
- 2.02x
- EPS (TTM)
- ₹2.61
- Book value / share
- ₹36.08
- ROE
- 7.23%
- ROCE
- 7.76%
- ROA
- 4.79%
- Debt / equity
- 0.36x
- Dividend yield
- 0%
- EBITDA margin
- 8.45%
- 52-week range
- ₹66 – ₹90.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Ishita Drugs & Industries Ltd (ISHITADR) reported revenue of ₹14.66 crore, net profit of ₹0.78 crore and earnings per share of ₹2.61. That compares with revenue of ₹15 crore and net profit of ₹0.87 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.06 crore and net profit ₹0.18 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 14.09 | 12.07 | 15.19 | 15 | 14.66 |
| Net profit (₹ cr) | 0.8 | 0.58 | 0.75 | 0.87 | 0.78 |
| EPS (₹) | 2.68 | 1.94 | 2.51 | 2.91 | 2.61 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.66% | 0.22% | 2.10% | -1.25% |
| Profit growth | 22.75% | 9.67% | 2.55% | 16.00% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.04% of Ishita Drugs & Industries Ltd (ISHITADR) (unchanged from the previous quarter). Market capitalisation was ₹22 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2001.
Largest disclosed public shareholders in Jun 2026: RAJAN MALHOTRA 3.34%, MAHENDRA GIRDHARILAL WADHWANI 2.15%, VIKKRAMM CHANDIRRAMANI 1.36%, SUMIT JAGDISHPRASAD AGRAWAL 1.1%, SANGEETHA S 1%, HUF 1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.04% | - | - | - | 49.96% |
| Mar 2026 | 50.04% | - | - | - | 49.96% |
| Dec 2025 | 50.04% | - | - | - | 49.96% |
| Sep 2025 | 49.96% | - | - | - | 50.04% |
| Jun 2025 | 49.92% | - | - | - | 50.08% |
| Mar 2025 | 49.91% | - | - | - | 50.09% |
| Dec 2024 | 49.84% | - | - | - | 50.16% |
| Sep 2024 | 49.8% | - | - | - | 50.2% |